Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$25.35 +3.8%	$22.45	$16.50 ▼ $26.55	$2.21B	N/A	60,467 shs	3,487 shs
GHRS GH Research	$12.08 -3.9%	$10.34	$6.00 ▼ $20.50	$628.50M	0.86	181,793 shs	180,560 shs
OGN Organon & Co.	$9.54 +4.2%	$11.15	$8.01 ▼ $23.10	$2.48B	0.75	3.29 million shs	6.85 million shs
XENE Xenon Pharmaceuticals	$29.04 +1.9%	$33.27	$26.74 ▼ $46.00	$2.23B	1.21	533,412 shs	1.88 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-5.38%	-2.75%	-3.40%	+23.38%	+2,442,999,900.00%
GHRS GH Research	+7.44%	+6.62%	+33.72%	+18.03%	-12.34%
OGN Organon & Co.	+0.44%	+8.43%	-28.04%	-39.04%	-56.34%
XENE Xenon Pharmaceuticals	-3.29%	-6.47%	-24.71%	-25.63%	-26.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	1.5625 of 5 stars	3.6	0.0	0.0	0.0	2.0	2.5	0.0
OGN Organon & Co.	4.922 of 5 stars	3.3	4.0	1.7	3.7	2.4	3.3	3.1
XENE Xenon Pharmaceuticals	3.5449 of 5 stars	4.5	4.0	0.0	0.0	3.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
GHRS GH Research	3.14	Buy	$30.43	151.89% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	88.78% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	88.77% Upside

Current Analyst Ratings Breakdown

Latest GHRS, AAPG, XENE, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.25	N/A	N/A	N/A	∞
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$6.29B	0.39	$3.06 per share	3.12	($0.27) per share	-35.31
XENE Xenon Pharmaceuticals	$7.50M	297.11	N/A	N/A	$14.18 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	-$35.59M	-$0.79	N/A	N/A	N/A	N/A	-20.29%	-19.49%	N/A
OGN Organon & Co.	$864M	$2.88	2.86	2.55	0.90	13.49%	431.62%	8.03%	8/5/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/14/2025 (Estimated)

Latest GHRS, AAPG, XENE, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.84%	+25.99%	2.78%	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest GHRS, AAPG, XENE, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
GHRS GH Research	N/A	15.83	15.83
OGN Organon & Co.	17.73	1.70	1.21
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
GHRS GH Research	56.90%
OGN Organon & Co.	77.43%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
GHRS GH Research	41.60%
OGN Organon & Co.	1.96%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.07 million	N/A	N/A
GHRS GH Research	10	52.03 million	30.38 million	Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable

GHRS, AAPG, XENE, and OGN Headlines

Recent News About These Companies

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28 at 3:10 AM | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27 at 4:31 AM | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27 at 4:27 AM | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26 at 3:49 AM | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26 at 3:12 AM | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 21, 2025 | marketbeat.com

Ensign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 19, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for XENE Earnings

May 18, 2025 | marketbeat.com

Sphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

HC Wainwright Issues Positive Outlook for XENE Earnings

May 17, 2025 | marketbeat.com

Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

MPM Bioimpact LLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 16, 2025 | marketbeat.com

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

May 15, 2025 | insidermonkey.com

Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events

May 15, 2025 | proactiveinvestors.co.uk

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, AAPG, XENE, and OGN Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$25.35 +0.92 (+3.77%)

As of 11:11 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

GH Research NASDAQ:GHRS

$12.08 -0.49 (-3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$12.12 +0.04 (+0.29%)

As of 04:04 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Organon & Co. NYSE:OGN

$9.54 +0.39 (+4.21%)

Closing price 03:59 PM Eastern

Extended Trading

$9.38 -0.16 (-1.68%)

As of 04:49 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Xenon Pharmaceuticals NASDAQ:XENE

$29.04 +0.55 (+1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$29.05 +0.01 (+0.03%)

As of 04:34 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time